AUS
NZ
UK
CA
USA
IND
Highlights
- In the financial year 2023, Alliance Pharma’s revenue surged by 29% to GBP 63.2 million
- In H1 FY23, cash from operations grew by 84.5%, driven by new marketing campaigns and refreshed packaging.
- The company has started initiatives towards becoming net zero emissions by 2030
Alliance Pharma PLC (LSE: APH) is an FTSE AIM UK 50 index-listed specialty pharmaceutical company. It is engaged in the acquisition, marketing, and distribution of pharmaceutical products. Moreover, APH’s operations span several therapeutic areas of the cardiovascular, consumer health, central nervous system, child health, endocrinology, gastroenterology, dermatology, obstetrics, gynaecology, etc.
In the financial year 2023, the company’s revenue grew by 29% to GBP 63.2 million, demonstrating strong consumer demand amidst the recovery of Kelo-Cote franchise, particularly in China. Similarly, cash from operations grew by 84.5% in the first half of FY23 compared to the prior corresponding period. The surge was driven by new marketing campaigns and refreshed packaging, aiding the Chinese distributors to expand the brand reach, leading to significantly increased market share for Nizoral.
Recent business update
On 26 April, the company announced publishing the preliminary results for the year ended 31st December 2023 on 8th May 2024.
Company outlook
Alliance Pharma is targeting growth in H2 with solid recovery in Kelo-Cote revenues. In addition, the company is under the plan to launch a new product whilst restarting the supply of products that have been destocked over a period.
Further, the company has started initiatives towards becoming net zero emissions by 2030 by installing photovoltaic panels.
Top 10 Shareholders
The top 10 shareholders of APH together account for approximately 64.69% of the total shareholdings in the company. DBAY Advisors, Ltd holds the maximum number of shares with around 21.09% shareholding, followed by Kempen Capital Management (UK) Ltd with around 10.21% shareholding, as depicted in the chart below:
Stock performance
The share price of APH has declined by about 12.14% in the last one month and over the last six months, it has decreased by around 12.05%. The stock has a 52-week low and 52-week high of GBX 33.57 and GBX 73.04, respectively. At present, it is trading lower than the average of 52-week high-low.
Note 1: Past performance is not a reliable indicator of future performance.
Note 2: The reference data for all price data, currency, technical indicators, support, and resistance levels is 1st May 2024. The reference data in this report has been partly sourced from EODHD/Others.
